Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls

Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is relevant to beneficial tumor response and surgical down-staging in patients of GCTB. However, these trials or case series have...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hengyuan, Gao, Junjie, Gao, Youshui, Lin, Nong, Zheng, Minghao, Ye, Zhaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567019/
https://www.ncbi.nlm.nih.gov/pubmed/33123484
http://dx.doi.org/10.3389/fonc.2020.580605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567019/
https://www.ncbi.nlm.nih.gov/pubmed/33123484
http://dx.doi.org/10.3389/fonc.2020.580605

Ejemplares similares